Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

PF-07976016

Stage Phase 2Stale

Sponsor Pfizer

Route oral

Sources

registry, as of 2026-02-06Stale

https://clinicaltrials.gov/study/NCT06717425

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Pfizer. Enrollment 263. Conditions Obesity. The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants w

ClinicalTrials.gov NCT06717425 protocol and results modules

registry, as of 2025-08-07Stale

https://clinicaltrials.gov/study/NCT06910839

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity. Overall status TERMINATED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 21. Conditions Overweight; Obesity. The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity. The total number of weeks of the study is up to approximately 22 weeks (5.5 months

ClinicalTrials.gov NCT06910839 protocol and results modules

Studies

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

Registry NCT06717425

Phase Phase 2

Status Completed

Enrollment 263

Start 2024-12-09

Primary completion 2025-10-23

Study completion 2026-01-12

Catalyst Primary completion. 2025-10-23. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

PF-07976016 Dose 1

Regimen once daily

Comparator placebo

Population Obesity

PF-07976016 Dose 2

Regimen once daily

Comparator placebo

Population Obesity

PF-07976016 Dose 3

Regimen once daily

Comparator placebo

Population Obesity

Placebo

Regimen once daily

Population Obesity

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in

Registry NCT06910839

Phase Phase 1

Status Terminated

Enrollment 21

Start 2025-03-13

Primary completion 2025-05-01

Study completion 2025-05-20

Catalyst Primary completion. 2025-05-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Period 1

Population Overweight; Obesity